Stock A038290 MACROGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Macrogen, Inc.

Equities

A038290

KR7038290003

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
20,050 KRW +0.80% Intraday chart for Macrogen, Inc. +3.62% -4.52%
2023 Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on October 21, 2022. CI
2023 Tranche Update on Macrogen, Inc.'s Equity Buyback Plan announced on October 21, 2022. CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025
Capitalization 1 291,718 193,743 209,560 200,080 -
Enterprise Value (EV) 2 291.7 181.6 209.6 211.1 217.1
P/E ratio 259 x -9.62 x -12.5 x 21.2 x 15.6 x
Yield - 1.57% - 1.5% 1.5%
Capitalization / Revenue - 1.4 x 1.58 x 1.35 x 1.21 x
EV / Revenue - 1.31 x 1.58 x 1.43 x 1.32 x
EV / EBITDA - 11.4 x 29.4 x 9.18 x 7.49 x
EV / FCF - -24.4 x - 70.4 x 27.1 x
FCF Yield - -4.1% - 1.42% 3.69%
Price to Book - 1.07 x - 1.21 x 1.14 x
Nbr of stocks (in thousands) 9,889 10,117 9,979 9,979 -
Reference price 3 29,500 19,150 21,000 20,050 20,050
Announcement Date 3/23/22 2/16/23 2/15/24 - -
1KRW in Million2KRW in Billions3KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025
Net sales 1 - 138.6 132.8 148 165
EBITDA 1 - 15.96 7.131 23 29
EBIT 1 - 5.293 -0.5032 11 15
Operating Margin - 3.82% -0.38% 7.43% 9.09%
Earnings before Tax (EBT) 1 - -25.94 -8.271 12 16
Net income 1 1.112 -20.01 -6.879 10.3 14
Net margin - -14.44% -5.18% 6.96% 8.48%
EPS 2 114.0 -1,990 -1,683 947.0 1,289
Free Cash Flow 3 - -7,450 - 3,000 8,000
FCF margin - -5,374.3% - 2,027.03% 4,848.48%
FCF Conversion (EBITDA) - - - 13,043.48% 27,586.21%
FCF Conversion (Net income) - - - 29,126.21% 57,142.86%
Dividend per Share 2 - 300.0 - 300.0 300.0
Announcement Date 3/23/22 2/16/23 2/15/24 - -
1KRW in Billions2KRW3KRW in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q3 2023 Q4
Net sales 1 - 29.74 35.55 38.04 - 36.92
EBITDA - - - - - -
EBIT 1 - 0.6388 0.122 1.632 - 1.573
Operating Margin - 2.15% 0.34% 4.29% - 4.26%
Earnings before Tax (EBT) - - - - - -
Net income 1 0.1621 -4.994 - - -1.977 -13.48
Net margin - -16.79% - - - -36.51%
EPS 50.00 - - - -198.0 -
Dividend per Share - - - - - -
Announcement Date 5/16/22 8/16/22 11/14/22 2/16/23 11/14/23 2/15/24
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025
Net Debt 1 - - - 11 17
Net Cash position 1 - 12.2 - - -
Leverage (Debt/EBITDA) - - - 0.4783 x 0.5862 x
Free Cash Flow 2 - -7,450 - 3,000 8,000
ROE (net income / shareholders' equity) - -10.3% -3.92% 5.8% 7.5%
ROA (Net income/ Total Assets) - -7.81% - 3.7% 5%
Assets 1 - 256.2 - 278.4 280
Book Value Per Share 3 - 17,826 - 16,604 17,610
Cash Flow per Share 3 - 1,070 - 5,123 5,632
Capex 1 - 18.2 - 18 18
Capex / Sales - 13.14% - 12.16% 10.91%
Announcement Date 3/23/22 2/16/23 2/15/24 - -
1KRW in Billions2KRW in Million3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Macrogen, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
20,050 KRW
Average target price
30,000 KRW
Spread / Average Target
+49.63%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MACROGEN, INC. Stock Macrogen, Inc.
-4.52% 145M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. A038290 Stock
  4. Financials Macrogen, Inc.